Leukemia & Lymphoma

Article	Citations
Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025	57
Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study	48
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults	40
Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies	34
Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination	31
Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies	31
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial	30
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature	30
Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States	30
Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells	28
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)	25
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study	25
lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p	24
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome	22
Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms	22
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia	22
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation	22
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome	21
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group	21
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort	20
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant	20
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma	19
CAR-T cell persistence in the treatment of leukemia and lymphoma	18
Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy	17
A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma	17

A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD	17
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas	17
Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies	17
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax	16
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia	16
Glofitamab CD20-TCB bispecific antibody	16
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study	16
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia	15
Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia	15
Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes	15
Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms	15
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia	15
CD5+ diffuse large B-cell lymphoma: a narrative review	15
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple m	14
Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia	14
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy *	14
Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy	14
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series	14
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience	14
Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult	13
Hyperleukocytosis and leukostasis in acute and chronic leukemias	13
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas	13
Idelalisib immune-related toxicity is associated with improved treatment response	13
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia	13
Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies	13
AML1-ETO inhibits acute myeloid leukemia immune escape by CD48	13
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia	13
Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections	13
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy	13
The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis	12
Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib	12
Targeting MALT1 for the treatment of diffuse large B-cell lymphoma	12
The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt	12
Novel therapeutics and targets in myelofibrosis	12
Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials	12
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	12
Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy	12
Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy	12
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from	12
Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW)	11
Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice	11
PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements	11
Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial	11
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients	11
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration	11
Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma	11
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees	11
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	11
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia	11
Momelotinib reduces transfusion requirements in patients with myelofibrosis	11

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management	11
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia	11
Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation	11
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study	11
A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia	11
Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020	11
Congenital acute myeloid leukemia: challenges and lessons. A 15-year experience from the UK	11
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial	11
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study	10
Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality	10
CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas	10
Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells	10
Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma	10
Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019	10
Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome	10
Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes	10
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia	10
Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia	10
Late onset neutropenia after rituximab and obinutuzumab treatment – characteristics of a class-effect toxicity	10
Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients	9
Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma	9
A novel nomogram based on prognostic factors for predicting venous thrombosis risk in lymphoma patients	9
A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma	9
Toxicity associated with high-dose intravenous methotrexate for hematological malignancies	9
Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System	9
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of tw	9
T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape	9
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy	9
Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy	9
Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study	9
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia	9
Treatment and outcome patterns of patients with Waldenström’s macroglobulinemia: a large, multicenter retrospective review in China	9
Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison	9
Upregulation of FHL1, SPNS3, and MPZL2 predicts poor prognosis in pediatric acute myeloid leukemia patients with FLT3-ITD mutation	9
miR-145-5p exerts anti-tumor effects in diffuse large B-cell lymphoma by regulating S1PR1/STAT3/AKT pathway	9
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study	9
Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia	9
Exercise training (ET) in adult and elderly patients receiving anti-lymphoma treatments is feasible and may improve the provision of care	9
Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study	9
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma	9
Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis	9
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients	9
SUVmax-based assessment of PET response shows a superior specificity to Deauville criteria for predicting recurrence in Hodgkin’s lymphoma	9
Artificial intelligence models in chronic lymphocytic leukemia – recommendations toward state-of-the-art	9
Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma	9
Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated lit	8
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 00	8
Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma	8
Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis	8
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia	8
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression	8
Infections in secondary immunodeficiency patients treated with Privigen®or Hizentra®: a retrospective US administrative claims study in patients with hematological malignancies	8
Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia	8
Co-occurring rearrangements of DUSP22 and TP63 define a rare genetic subset of ALK-negative anaplastic large cell lymphoma with inferior survival outcomes	8
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis	8
Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy	8
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKITmutation relapse post allo-HSCT	8
Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) – a new perspective	8
Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?	8
The role of PI3K inhibitors in the treatment of malignant lymphomas	8
A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia	8
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma	8
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial	8
Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensiv	8
Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia	8
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL	8
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi	8
3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance	8
Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas	8
Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma	8
Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the	8
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance	8
Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression	8
The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria	7
Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience	7
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?	7
Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lym	7
Excess mortality in younger patients with myeloproliferative neoplasms	7
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	7
Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era	7

Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting	7
Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents	7
Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma	7
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor	7
Targeting mitochondrial metabolism in acute myeloid leukemia	7
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis	7
Central nervous system involvement by mantle cell lymphoma	7
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma	7
CD303 (BDCA-2) – a potential novel target for therapy in hematologic malignancies	7
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)	7
Mitochondrial metabolism: powering new directions in acute myeloid leukemia	7
Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm	7
Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia	7
Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate	7
Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities	7
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia	7
Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab	7
Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-wor	7
Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations	7
Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome	7
The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia	7
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*	7
Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma	7
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute	7
Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience	7
Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom	7
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis	7
RNA-binding proteins as drivers of AML and novel therapeutic targets	7
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas	7
High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis	7
Body mass index and survival of patients with lymphoma	7
Specific TCR V–J gene segment recombinations leading to the identification pan-V–J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma	7
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy	7
Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility	7
Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies	7
Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning	7
Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review	7
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed folli	6
CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab	6
Interdisciplinary approach to multiple myeloma – time to diagnosis and warning signs	6
The regulation of bcr-abl in hypoxia is through the mTOR pathway	6
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome	6
KLF4 inhibition by Kenpaullone induces cytotoxicity and chemo sensitization in B-NHL cell lines via YY1 independent	6
Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases	6
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax	6
Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing	6
Racial disparities in the use of palliative radiotherapy for black patients with multiple myeloma in the United States	6
XX International workshop on chronic lymphocytic leukemia	6
A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance	6
Persistent fatigue among long-term non-Hodgkin lymphoma survivors	6
Burkitt lymphoma – no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy	6
Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transpl	6
Grade 3–4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation	6
Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation	6
The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma	6
Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma	6
Familial platelet disorder due to germline exonic deletions inRUNX1: a diagnostic challenge with distinct alterations of the transcript isoform equilibrium	6
STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms	6
Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients	6
Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation	6
Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia	6
CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement	6
Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation	6
Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data	6
Tumor suppressors in acute myeloid leukemia	6
Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia	6
Donor derived leukemia in allogeneic transplantation	6
Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy	6
Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment	6
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study	6
A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands	6
Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation	6
Trametinib enhances ATRA-induced differentiation in AML cells	6
Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia	6
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients	6
Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation	6
Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma	6
Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country	6
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance	6
Hyperpigmented mycosis fungoides: a retrospective and comparative analysis with other subtypes of mycosis fungoides	6
CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage	6
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma	5
BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival	5
At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China	5
NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980–2017: a nationwide cohort study	5
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	5
Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center	5
Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia	5
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	5
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	5
Thrombosis in multiple myeloma: mechanisms, risk assessment and management	5
Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient	5
ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies	5
Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population	5
Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL	5